​

Funding Round

Series B - Taysha Gene Therapies

Series B - Taysha Gene Therapies

Investment Firm

Overview

Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.

Announced Date

Aug 05, 2020

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Fidelity

Fidelity

Fidelity is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and secondary_market and seed firm.

Participant Investors

12

Investor Name
Participant InvestorInvus
Participant InvestorGoogle Ventures
Participant InvestorFidelity
Participant InvestorFranklin Templeton
Participant InvestorBlackRock

Round Details and Background

Taysha Gene Therapies raised $95000000 on 2020-08-05 in Series B

Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.

Company Funding History

8

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Nov 03, 2022
Post-IPO Equity - Taysha Gene Therapies
-3.0M
Aug 14, 2023
Post-IPO Equity - Taysha Gene Therapies
11-150.0M
Dec 19, 2023
Post-IPO Debt - Taysha Gene Therapies
1-40.0M
Jun 26, 2024
Post-IPO Equity - Taysha Gene Therapies
-75.0M

Recent Activity

There is no recent news or activity for this profile.